Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.04 USD

29.04
4,151,466

-0.05 (-0.17%)

Updated Sep 30, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Moderna (MRNA) Up on Plans to Get Omicron Booster Ready in 2022

Moderna (MRNA) plans to begin clinical development of its Omicron-specific variant vaccine early in 2022 and expects to make it available for the public in the fall of 2022.

Sarepta's (SRPT) DMD Gene Therapy Study Data Fails to Impress

Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.

Best Growth Stocks to Buy for January 11th

AN, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 11, 2022

Sanghamitra Saha headshot

Omicron Vaccines to Hit Market Soon? ETF Areas to Benefit

Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.

Zacks.com featured highlights include: TotalEnergies SE, Nutrien, FedEx Corp. and Pfizer Inc.

TotalEnergies SE, Nutrien, FedEx Corp. and Pfizer Inc. are included in this screen of the week article.

Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised)

Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.

Why the Earnings Surprise Streak Could Continue for Pfizer (PFE)

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View

Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.

AstraZeneca (AZN) Inks Deal to Develop ATTR-CM Candidate

AstraZeneca (AZN) inks collaboration and license agreement with Neurimmune AG to develop/commercialize the latter's NI006 for treating transthyretin amyloid cardiomyopathy.

Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines

Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.

The Zacks Analyst Blog Highlights: Pfizer, AbbVie, Eli Lilly and J&J

Pfizer, AbbVie, Eli Lilly and J&J are included in this analyst blog.

Rimmi Singhi headshot

4 Lucrative Bets Boasting High Earnings Yield

TotalEnergies SE (TTE), Nutrien (NTR), FedEx (FDX) and Pfizer (PFE) could be some attractive bets if you are looking for high earnings yield picks.

AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS

AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.

Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies

Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.

Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt

Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.

Exelixis (EXEL) Amends Agreement With Iconic Therapeutics

Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.

Lilly (LLY) Inks Deal for Multiple Neurologic Indications

Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE Booster for Age 12-15, Breakthrough Tag to ABBV Drug

FDA authorizes Pfizer's (PFE) booster shot for adolescents 12 -15 years of age and grants Breakthrough Therapy tag to AbbVie's (ABBV) lung cancer candidate.

Zacks Investment Ideas feature highlights: AbbVie, Inc. and Pfizer Inc

AbbVie, Inc. and Pfizer Inc are highlighted in this investment idea article.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $54.84, marking a -1.42% move from the previous day.

Moderna (MRNA) Begins Dosing in Study on Vaccine Against EBV

Moderna (MRNA) doses the first participant in a phase I study evaluating its Epstein-Barr virus vaccine candidate, mRNA-1189.

4 Reasons Why You Should Add AbbVie (ABBV) to Your Portfolio

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Pfizer and BioNTech to Make mRNA-Based Shingles Vaccine

Pfizer (PFE) and BioNTech (BNTX) plan to develop an mRNA-based vaccine for shingles after witnessing success with their COVID-19 vaccine.

Company News for Jan 6, 2022

Companies In The News Are: PFE, LULU, NKE, T, VZ.